Skip to main content
Top
Published in: AIDS and Behavior 3/2020

01-03-2020 | Human Immunodeficiency Virus | Original Paper

How Male Sex Workers and Their Clients Shifted from Reluctance About HIV Pre-exposure Prophylaxis to Advocating for Its Use: A Longitudinal Mixed Methods Study

Authors: James MacGibbon, Victor Minichiello, Garrett Prestage, Stephen Bell, Cameron Cox, Basil Donovan, Denton Callander

Published in: AIDS and Behavior | Issue 3/2020

Login to get access

Abstract

We assessed individual and collective responses to HIV pre-exposure prophylaxis (‘PrEP’) among a network of male sex workers and clients. From 2011 to May 2017, keyword searches on an online discussion forum identified 668 posts that referenced PrEP. We conducted four analyses: (i) discourse analysis identifying reactions to PrEP, (ii) thematic analysis constructing rhetorical strategies, (iii) content analysis comparing discursive positions and rhetorical strategies, and (iv) longitudinal analyses assessing trends over time. Forum posts adopted one of three discursive positions (reluctance, interest, advocacy), drawing upon four non-exclusive strategies (deference to experts and evidence, acknowledging personal and shared experiences, establishing philosophical arguments, engaging in speculation). Posts from sex workers were more likely than clients to be supportive of PrEP (96% vs. 42%; χ2 = 18.46, p < 0.001) while over time this network moved from being predominantly reluctant about PrEP (61% of posts in 2012) to advocating for its use (65% of posts in 2017; Z = 5.01, p < 0.001).
Literature
1.
go back to reference Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587.CrossRef Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587.CrossRef
2.
go back to reference Cohen MS, Muessig K, Smith M, Powers K, Kashuba A. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS. 2012;26:1585–98.CrossRef Cohen MS, Muessig K, Smith M, Powers K, Kashuba A. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS. 2012;26:1585–98.CrossRef
3.
go back to reference Wright E, Grulich A, Roy K, et al. Australasian Society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018. J Virus Erad. 2018;4(2):143–59.PubMedPubMedCentral Wright E, Grulich A, Roy K, et al. Australasian Society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018. J Virus Erad. 2018;4(2):143–59.PubMedPubMedCentral
5.
go back to reference Cairns G, McCormack S, Molina JM. The European preexposure prophylaxis revolution. Curr Opin HIV AIDS. 2016;11(1):74–9.CrossRef Cairns G, McCormack S, Molina JM. The European preexposure prophylaxis revolution. Curr Opin HIV AIDS. 2016;11(1):74–9.CrossRef
6.
go back to reference WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2016. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2016.
7.
go back to reference Zablotska IB. Likely impact of pre-exposure prophylaxis on HIV epidemics among men who have sex with men. Sex Health. 2017;14(1):97–105.CrossRef Zablotska IB. Likely impact of pre-exposure prophylaxis on HIV epidemics among men who have sex with men. Sex Health. 2017;14(1):97–105.CrossRef
8.
go back to reference Holt M. Progress and challenges in ending HIV and AIDS in Australia. AIDS Behav. 2017;21(2):331–4.CrossRef Holt M. Progress and challenges in ending HIV and AIDS in Australia. AIDS Behav. 2017;21(2):331–4.CrossRef
9.
go back to reference Kippax S, Stephenson N. Socialising the biomedical turn in HIV prevention. London: Anthem Press; 2016. Kippax S, Stephenson N. Socialising the biomedical turn in HIV prevention. London: Anthem Press; 2016.
10.
go back to reference Nguyen MV, O’Malley MJ, Pirkle MC. Remedicalizing an epidemic: from HIV treatment as prevention to HIV treatment is prevention. AIDS. 2011;25(11):1435.CrossRef Nguyen MV, O’Malley MJ, Pirkle MC. Remedicalizing an epidemic: from HIV treatment as prevention to HIV treatment is prevention. AIDS. 2011;25(11):1435.CrossRef
11.
go back to reference Minichiello V, Scott J. Male sex work and society. New York: Harrington Park Press; 2014.CrossRef Minichiello V, Scott J. Male sex work and society. New York: Harrington Park Press; 2014.CrossRef
12.
go back to reference Mgbako O, Park SH, Mayer KH, et al. Transactional sex and preferences for pre-exposure prophylaxis (PrEP) administration modalities among men who have sex with men (MSM). J Sex Res. 2019;56:650.CrossRef Mgbako O, Park SH, Mayer KH, et al. Transactional sex and preferences for pre-exposure prophylaxis (PrEP) administration modalities among men who have sex with men (MSM). J Sex Res. 2019;56:650.CrossRef
13.
go back to reference Beyrer C, Crago AL, Bekker LG, et al. An action agenda for HIV and sex workers. Lancet. 2015;385(9964):287–301.CrossRef Beyrer C, Crago AL, Bekker LG, et al. An action agenda for HIV and sex workers. Lancet. 2015;385(9964):287–301.CrossRef
14.
go back to reference Underhill K, Morrow KM, Colleran CM, et al. Access to healthcare, HIV/STI testing, and preferred pre-exposure prophylaxis providers among men who have sex with men and men who engage in street-based sex work in the US. PLoS ONE. 2014;9(11):e112425.CrossRef Underhill K, Morrow KM, Colleran CM, et al. Access to healthcare, HIV/STI testing, and preferred pre-exposure prophylaxis providers among men who have sex with men and men who engage in street-based sex work in the US. PLoS ONE. 2014;9(11):e112425.CrossRef
15.
go back to reference Willig C. Beyond appearances: a critical realist approach to social constructionist work. In: Nightingale JD, Cromby J, editors. Social constructionist psychology: a critical analysis of theory and practice. Buckingham: Open University Press; 1999. Willig C. Beyond appearances: a critical realist approach to social constructionist work. In: Nightingale JD, Cromby J, editors. Social constructionist psychology: a critical analysis of theory and practice. Buckingham: Open University Press; 1999.
16.
17.
go back to reference Potter J, Wetherell M. Discourse and social psychology: beyond attitudes and behaviour. Thousand Oaks: SAGE; 1987. Potter J, Wetherell M. Discourse and social psychology: beyond attitudes and behaviour. Thousand Oaks: SAGE; 1987.
18.
go back to reference Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.CrossRef Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.CrossRef
19.
go back to reference Krippendorff K. Content analysis: an introduction to its methodology. Thousand Oaks: Sage; 2012. Krippendorff K. Content analysis: an introduction to its methodology. Thousand Oaks: Sage; 2012.
20.
go back to reference Wilcoxon F. Individual comparisons by ranking methods. Biometrics. 1945;1:80–3.CrossRef Wilcoxon F. Individual comparisons by ranking methods. Biometrics. 1945;1:80–3.CrossRef
21.
go back to reference Kippax S. Understanding and integrating the structural and biomedical determinants of HIV infection: a way forward for prevention. Curr Opin HIV AIDS. 2008;3(4):489–94.CrossRef Kippax S. Understanding and integrating the structural and biomedical determinants of HIV infection: a way forward for prevention. Curr Opin HIV AIDS. 2008;3(4):489–94.CrossRef
22.
go back to reference Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–83.CrossRef Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–83.CrossRef
23.
go back to reference McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRef McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRef
24.
go back to reference Weick KE. Sensemaking in organisations. London: Sage; 1995. Weick KE. Sensemaking in organisations. London: Sage; 1995.
25.
go back to reference Weick KE, Sutcliffe KM, Obstfeld D. Organizing and the process of sensemaking. Organ Sci. 2005;16(4):409–21.CrossRef Weick KE, Sutcliffe KM, Obstfeld D. Organizing and the process of sensemaking. Organ Sci. 2005;16(4):409–21.CrossRef
27.
go back to reference Holt M, Lea T, Schmidt HM, et al. Willingness to use and have sex with men taking HIV pre-exposure prophylaxis (PrEP): results of online surveys of Australian gay and bisexual men, 2011-2015. Sex Transm Infect. 2017;93(6):438–44.CrossRef Holt M, Lea T, Schmidt HM, et al. Willingness to use and have sex with men taking HIV pre-exposure prophylaxis (PrEP): results of online surveys of Australian gay and bisexual men, 2011-2015. Sex Transm Infect. 2017;93(6):438–44.CrossRef
28.
go back to reference Lea T, Kolstee J, Murphy D, et al. Changing attitudes to and engagement with biomedical HIV prevention by gay and bisexual men: key findings from the PrEPARE Project 2017. Sydney: Centre for Social Research in Health, UNSW Sydney; 2017. Lea T, Kolstee J, Murphy D, et al. Changing attitudes to and engagement with biomedical HIV prevention by gay and bisexual men: key findings from the PrEPARE Project 2017. Sydney: Centre for Social Research in Health, UNSW Sydney; 2017.
Metadata
Title
How Male Sex Workers and Their Clients Shifted from Reluctance About HIV Pre-exposure Prophylaxis to Advocating for Its Use: A Longitudinal Mixed Methods Study
Authors
James MacGibbon
Victor Minichiello
Garrett Prestage
Stephen Bell
Cameron Cox
Basil Donovan
Denton Callander
Publication date
01-03-2020
Publisher
Springer US
Published in
AIDS and Behavior / Issue 3/2020
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02618-1

Other articles of this Issue 3/2020

AIDS and Behavior 3/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.